Nieuws

Kisunla werd aanvankelijk goedgekeurd door de FDA in juli 2024 op basis van de TRAILBLAZER-ALZ 2 Fase 3 klinische ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...
The FDA has updated the labeling for Kisunlaâ„¢ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.
Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...
Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease Provided by PR Newswire Jul 9, 2025, 10:45:00 AM ...
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease Jul. 09, 2025 6:45 AM ET Eli Lilly and Company (LLY) ...
The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...
Microcap Cognition Therapeutics (NASDAQ:CGTX) has skyrocketed 35% in Thursday trading after stating the company had a ...